Repeated 7-OH-DPAT treatments: behavioral sensitization, dopamine synthesis and subsequent sensitivity to apomorphine and cocaine

Mattingly, Bruce A.; Fields, Sonia E; Langfels, Mike; Rowlett, James K.; Robinet, P. M.; Bardo, Michael T.

doi:10.1007/bf02247390

Cited by 18 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following repeated administration, 7-OH-DPAT co-administered with d-amphetamine produced sensitization of locomotion on the ascending limb of the d-amphetamine dose-response curve (0.5 mg/kg), but decreased locomotion on the descending limb (5-10 mg/kg) relative to acute administration. The sensitization of locomotion seen on the ascending limb is inconsistent with previous findings that indicate that pretreatment with 7-OH-DPAT did not produce cross-sensitization of acute apomorphine-or cocaine-induced locomotion (Mattingly 1996). Thus, it may be necessary to co-administer 7-OH-DPAT with a non-selective direct or indirect DA agonist in order for 7-OH-DPAT to facilitate behavioral sensitization.…”

Section: Effects Of 7-oh-dpat On D-amphetamine-induced Motor Behaviorscontrasting

confidence: 44%

“…Thus, it is possible that 7-OH-DPAT produces its discriminative stimulus effects via stimulation of D 2 and/or D 3 presynaptic receptors (Sanger et al 1997). An alternative hypothesis is that behavioral suppression is due to stimulation of post-synaptic D 3 receptors (Waters et al 1993;Svensson et al 1994a,b;Mattingly et al 1996), such that behaviors produced by postsynaptic D 3 receptor stimulation may oppose behaviors produced by stimulation of other DA receptors resulting in attenuation of d-amphetamine-induced behaviors. Consistent with this hypothesis, pre-administration of 7-OH-DPAT (0.01-0.1 mg/kg) enhances the discriminative stimulus effects of cocaine (Spealman 1996).…”

Section: Possible Mechanisms Of the Effects Of 7-oh-dpat On D-amphetamentioning

confidence: 98%

See 1 more Smart Citation

Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference

et al. 1998

View full text Add to dashboard Cite

Low doses of the dopamine D3-preferring agonist 7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) produce a behavioral profile that is opposite to that produced by the psychomotor stimulants cocaine and amphetamine. For example, low doses of 7-OH-DPAT produce conditioned place aversion and hypolocomotion, whereas psychomotor stimulants produce conditioned place preference (CPP) and hyperlocomotion. In experiment 1, the effects of low doses of 7-OH-DPAT (0.01-0.1 mg/kg) on d-amphetamine-induced (1 mg/kg) motor behaviors and CPP were assessed. In experiment 2, the effects of 0.1 mg/kg 7-OH-DPAT on d-amphetamine (0-10 mg/kg) dose-response curves for the same behaviors were examined. During conditioning, drug injections were paired with a distinct compartment, whereas saline injections were paired with another compartment. Locomotion and headbobbing were measured following acute and repeated drug administration during conditioning and place conditioning was assessed 24 h following the last conditioning day. In experiment 1, d-amphetamine-induced locomotion was dose-dependently decreased by 7-OH-DPAT following repeated administration, which was probably due to the emergence of headbobbing, a behavior not observed with d-amphetamine alone. d-Amphetamine-CPP was not altered by co-administration of 0-0.03 mg/kg 7-OH-DPAT, but was attenuated by co-administration of 0.1 mg/kg 7-OH-DPAT. In experiment 2, 7-OH-DPAT co-administered with low doses of d-amphetamine (0-0.5 mg/kg) produced a decrease in locomotion following acute administration. However, 7-OH-DPAT produced sensitization of locomotion at the 0.5 mg/kg dose of d-amphetamine and an increase in headbobbing at the 0.5-10 mg/kg doses of d-amphetamine following repeated administration. In contrast, d-amphetamine-CPP was attenuated by co-administration of 7-OH-DPAT. These findings suggest that 0.1 mg/kg 7-OH-DPAT attenuates the reinforcing effects of d-amphetamine despite enhancing stereotypic behaviors.

show abstract

Section: Effects Of 7-oh-dpat On D-amphetamine-induced Motor Behaviorscontrasting

confidence: 44%

Section: Possible Mechanisms Of the Effects Of 7-oh-dpat On D-amphetamentioning

confidence: 98%

Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference

et al. 1998

View full text Add to dashboard Cite

show abstract

“…These potential interactions highlight a proposed model in which D3 receptor stimulation contributes to sensitization through interaction with other systems, but is insufficient to account for sensitization independent of other systems. Thus, the proposed model does not contradict the failure of repetitive treatment with D3-selective doses of 7-OH-DPAT to induce sensitization (Mattingly et al, 1996). For example, increased dopaminergic cell activity because of alterations in glutamatergic activity in ventral tegmentum during early withdrawal stages from cocaine and amphetamine (Henry et al, 1989;Zhang et al, 1997;White et al, 1995) could be expected to result in increased impulse-dependent dopamine release in terminal fields.…”

Section: Locus Of D3 Receptor-mediated Inhibitory Effectsmentioning

confidence: 92%

Altered Behavioral Response to Dopamine D3 Receptor Agonists 7-OH-DPAT and PD 128907 Following Repetitive Amphetamine Administration

Richtand

Welge

Levant

et al. 2003

Neuropsychopharmacol

View full text Add to dashboard Cite

Behavioral sensitization, the progressive and enduring enhancement of certain behaviors following repetitive drug use, is mediated in part by dopaminergic pathways. Increased locomotor response to drug treatment, a sensitizable behavior, is modulated by an opposing balance of dopamine receptor subtypes, with D1/D2 dopamine receptor stimulation increasing and D3 dopamine receptor activation inhibiting amphetamine-induced locomotion. We hypothesize that tolerance of D3 receptor locomotor inhibition contributes to behavioral sensitization. In order to test the hypothesis that expression of behavioral sensitization results in part from release of D3 receptor-mediated inhibition, thereby resulting in decreased response to D3 receptor agonists, we examined the effect of repetitive amphetamine administration on the behavioral response to the D3 receptor preferring agonists 7-OH-DPAT and PD 128907. D3-selective effects have recently been described for both drugs at a low dose. At 1 week following completion of a repetitive treatment regimen, amphetamine-pretreated rats displayed a decreased response to D3-selective doses of both 7-OH-DPAT and PD 128907, when compared to animals receiving saline pretreatment. Moreover, in addition to the quantitative alteration in response, there was a change in the inter-relation between response to amphetamine and D3 agonist. A highly significant inverse relation between locomotor inhibitory response to PD 128907 and the locomotor-stimulant response to amphetamine was observed prior to amphetamine treatment. In contrast, 10 days following repetitive amphetamine treatment, the relation between response to PD 128907 and amphetamine was not detected. The observed behavioral alteration could not be accounted for by changes in D3 receptor binding in ventral striatum. These findings suggest a persistent release of D3 receptor-mediated inhibitory influence contributes to the expression of behavioral sensitization to amphetamine.

show abstract

“…This behavioral sensitization e¤ect has been demonstrated after the chronic administration of the selective dopamine D 2 receptor agonist, bromocriptine Wise 1992, 1993) and the D 2 /D 3 receptor agonist, quinpirole (e.g., Szechtman et al 1994). Recently, we found similar acute and chronic locomotor e¤ects after the administration of the putative selective dopamine D 3 receptor agonist 7-OH-DPAT (Mattingly et al 1996). But, while behavioral sensitization to 7-OH-DPAT was similar to that of quinpirole, a number of di¤erences were also apparent.…”

Section: Introductionmentioning

confidence: 86%

“…For example, rats sensitized to quinpirole have been reported to display cross-sensitization to apomorphine . In contrast, rats sensitized to 7-OH-DPAT, like bromocriptine (Ho¤man and Wise 1993), do not display cross-sensitization to either apomorphine or cocaine (Mattingly et al 1996). Further, chronic quinpirole treatments produce an increase in basal dopamine synthesis in both nigrostriatal and mesolimbic terminal Þelds, presumably due to the development of autoreceptor subsensitivity (Rowlett et al 1995).…”

Section: Introductionmentioning

confidence: 87%

Effects of selective dopamine D 1 - and D 2 -type receptor antagonists on the development of behavioral sensitization to 7-OH-DPAT

et al. 1998

Self Cite

View full text Add to dashboard Cite

The primary objective of this study was to determine whether the development of behavioral sensitization to the putative dopamine D3 receptor agonist 7-OH-DPAT could be prevented by either selective D1-type or D2-type dopamine receptor antagonists. In three experiments, male Wistar rats (250-350 g) were given seven to nine injections (at 48-h intervals) of 7-OH-DPAT (1.0 mg/kg, SC) or vehicle in combination with the D2-type dopamine antagonist eticlopride (0.3 mg/kg, SC), the D1-type dopamine antagonist SCH 23390 (0.1 or 0.2 mg/kg, SC), or vehicle. After the injections, the rats were tested for locomotor activity in photocell arenas for 2 h. In the first two experiments, after seven injections, all rats were tested for activity following vehicle injections to test for possible conditioning effects. In each experiment, after the last pre-exposure session, all rats were given a challenge injection of 7-OH-DPAT (1.0 mg/kg, SC) and tested for activity. Major findings were as follows: a) 7-OH-DPAT treatments produced a progressively greater increase in locomotor activity with repeated treatment; b) concurrent treatment with eticlopride or SCH 23390 (0.1 and 0.2 mg/kg) blocked the acute locomotor-activating effects of 7-OH-DPAT across days; c) eticlopride, but not SCH 23390, completely blocked the development of behavioral sensitization to 7-OH-DPAT. Although the low dose of SCH 23390 (0.1 mg/kg) produced a partial attenuation of sensitization, the higher dose (0.2 mg/kg) of SCH 23390 appeared to augment, rather than block, sensitization to 7-OH-DPAT; d) rats previously treated with SCH 23390 (0.2 mg/kg, but not 0.1 mg/kg) without 7-OH-DPAT displayed a hyperactive response to the 7-OH-DPAT challenge injection; and e) after vehicle injections, rats previously given 7-OH-DPAT, SCH 23390, or eticlopride either alone or in combination were more active than vehicle control rats. These findings suggest that the neurochemical mechanisms mediating the development of behavioral sensitization to 7-OH-DPAT may differ from those of other dopamine D2-type agonists such as quinpirole or bromocriptine. Moreover, these results demonstrate that hyperactivity responses following vehicle injections in drug-pretreated animals do not necessarily reflect conditioning mechanisms.

show abstract

Repeated 7-OH-DPAT treatments: behavioral sensitization, dopamine synthesis and subsequent sensitivity to apomorphine and cocaine

Cited by 18 publications

References 32 publications

Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference

Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference

Altered Behavioral Response to Dopamine D3 Receptor Agonists 7-OH-DPAT and PD 128907 Following Repetitive Amphetamine Administration

Effects of selective dopamine D 1 - and D 2 -type receptor antagonists on the development of behavioral sensitization to 7-OH-DPAT

Contact Info

Product

Resources

About